Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT

Open source

DOI: 10.1016/s1470-2045(21)00375-2
Published: 2021 Oct
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-21-00375-2,
  title = {Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.},
  author = {Schuster SJ and Tam CS and Borchmann P and Worel N and McGuirk JP and Holte H and Waller EK and Jaglowski S and Bishop MR and Damon LE and Foley SR and Westin JR and Fleury I and Ho PJ and Mielke S and Teshima T and Janakiram M and Hsu JM and Izutsu K and Kersten MJ and Ghosh M and Wagner-Johnston N and Kato K and Corradini P and Martinez-Prieto M and Han X and Tiwari R and Salles G and Maziarz RT},
  year = {2021},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(21)00375-2},
  url = {https://doi.org/10.1016/s1470-2045(21)00375-2}
}

RIS

TY  - JOUR
TI  - Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
AU  - Schuster SJ
AU  - Tam CS
AU  - Borchmann P
AU  - Worel N
AU  - McGuirk JP
AU  - Holte H
AU  - Waller EK
AU  - Jaglowski S
AU  - Bishop MR
AU  - Damon LE
AU  - Foley SR
AU  - Westin JR
AU  - Fleury I
AU  - Ho PJ
AU  - Mielke S
AU  - Teshima T
AU  - Janakiram M
AU  - Hsu JM
AU  - Izutsu K
AU  - Kersten MJ
AU  - Ghosh M
AU  - Wagner-Johnston N
AU  - Kato K
AU  - Corradini P
AU  - Martinez-Prieto M
AU  - Han X
AU  - Tiwari R
AU  - Salles G
AU  - Maziarz RT
PY  - 2021
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(21)00375-2
UR  - https://doi.org/10.1016/s1470-2045(21)00375-2
ER  -

APA

SJ, S., CS, T., P, B., N, W., JP, M., H, H., EK, W., S, J., MR, B., LE, D., SR, F., JR, W., I, F., PJ, H., S, M., T, T., M, J., JM, H., K, I., MJ, K., M, G., N, W., K, K., P, C., M, M., X, H., R, T., G, S., & RT, M. (2021). Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(21)00375-2

Source records

pubmed · retrieved 2026-09-26T12:10:26.555Z